Eagle Pharmaceuticals v. Baxter International: Dismissed With Prejudice After 838 Days
Eagle Pharmaceuticals sued Baxter International in the District of Delaware alleging infringement of two patents covering its BELRAPZO bendamustine hydrochloride injection. The parties reached a settlement agreement, and the case was dismissed with prejudice after 838 days of litigation, with each side bearing its own costs and attorneys' fees.
Eagle v. Baxter: A Two-Year Bendamustine Patent Battle Ends in Settlement
Eagle Pharmaceuticals, Inc. filed suit against Baxter International, Inc. on January 17, 2024 in the U.S. District Court for the District of Delaware (Case No. 1:24-cv-00066) before Judge Jennifer L. Hall. Eagle asserted two patents — US11844783B2 and US11872214B2 — in connection with its BELRAPZO product, a bendamustine hydrochloride injection. The action was framed as a patent infringement claim against Baxter's competing product activities in the bendamustine oncology space.
The recorded basis of termination is Dismissed with Prejudice. The docket order states that the parties entered into a settlement agreement and filed a stipulated dismissal under Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), pursuant to which Eagle's claims against Baxter were dismissed with prejudice and Baxter's counterclaims were dismissed as moot. The court retained jurisdiction to enforce and resolve disputes arising under the settlement agreement. All parties were to bear their own costs and attorneys' fees. The specific terms of the underlying settlement agreement are not disclosed in the available record.
The case ran for 838 days — well past the median time to resolution for patent cases in Delaware — before the parties agreed to resolve their dispute. The mutual cost-bearing provision and the court's retained jurisdiction to enforce the settlement agreement are consistent with a negotiated resolution, though the commercial terms driving that resolution are not disclosed in the public record. What remains unknown is whether any licensing, supply, or market-access arrangements underpin the settlement.
See Complete Case & Patent Analysis →Filing to Dismissed with Prejudice in 838 days
838 days from filing to dismissal — over two years of active Delaware District Court litigation
US11844783B2 and US11872214B2 — Bendamustine Hydrochloride Injection Formulations
Any company developing, manufacturing, or marketing a bendamustine hydrochloride injection product — whether a branded competitor or a 505(b)(2) / ANDA applicant — should consider a structured FTO assessment against both Eagle patents. The absence of any court-issued invalidity ruling in this case means neither patent has been judicially weakened. R&D and regulatory teams working on injectable bendamustine formulations are the primary audience for this risk assessment.
Official order — verbatim text
The stipulated dismissal order reflects a settlement-driven resolution in which Eagle's infringement claims were extinguished with prejudice and Baxter's counterclaims — including any invalidity challenges — were dismissed as moot without adjudication. The court's retention of jurisdiction to enforce the settlement agreement distinguishes this from a simple walk-away, suggesting ongoing obligations between the parties, the specifics of which are not disclosed in the available record.
Dismissed with prejudice: what the stipulated resolution means for both parties
Dismissal with prejudice following a Rule 41 stipulation
The case was terminated via a stipulated dismissal under FRCP 41(a)(1)(A)(ii) and 41(c), signed by all parties. A dismissal with prejudice is a final adjudication on the merits as a matter of law: Eagle cannot re-file the same claims against Baxter on these patents arising from the same conduct. The court retained jurisdiction to enforce any disputes arising under the settlement agreement — an important structural feature that gives the settlement agreement teeth beyond the dismissal order itself.
FRCP 41(a)(1)(A)(ii) stipulated dismissalEagle's claims resolved with finality — no re-filing possible
For Eagle Pharmaceuticals, dismissal with prejudice forecloses any future action against Baxter on the same patents (US11844783B2 and US11872214B2) for the conduct at issue. The retention of court jurisdiction to enforce the settlement agreement suggests Eagle secured some form of ongoing protection or commitment, though the specific terms are not disclosed in the available record. Eagle's two asserted patents remain in force and enforceable against third parties.
Patents remain enforceable against third partiesBaxter's counterclaims dismissed as moot — no merits ruling on validity
Baxter's counterclaims — likely including patent invalidity challenges — were dismissed as moot, meaning no court ruling was issued on the validity or enforceability of Eagle's two patents. This is commercially significant: the patents survive with no adverse validity determination on the public record. Baxter bears its own costs and attorneys' fees. The specific obligations or rights Baxter may have secured under the settlement agreement are not disclosed in the available record.
No invalidity ruling — patents intactBendamustine IP landscape remains intact for Eagle post-settlement
With no validity ruling issued and both patents surviving the litigation intact, Eagle's IP position around BELRAPZO bendamustine hydrochloride injection formulations is undiminished by this proceeding. Competitors and generic entrants in the bendamustine space cannot point to this case as precedent weakening Eagle's portfolio. The mutual cost-bearing provision is consistent with a negotiated commercial resolution, though the underlying commercial terms are not disclosed in the available record.
Eagle patents unimpaired by this proceedingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eagle Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Baxter International, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Alexander T. Hornat | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kelly Welsh | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kenneth G. Schuler | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Maliheh Zare | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Manuela Burek | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Marc N. Zubick | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle Chin | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Wyley S. Proctor | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Amanda K. Antons | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew Mark Moshos | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Judah Bellin | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Martin J. Black | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Noah M. Leibowitz | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Philip A. Rovner | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant law firm | Potter Anderson & Corroon, LLP | Law Firm | Representing Baxter International, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the bendamustine and injectable oncology formulation space
Forward-looking patent and R&D intelligence derived from Eagle Pharmaceuticals v. Baxter International — covering portfolio activity, filing trends, and white space in bendamustine HCl injection technology.
Eagle Pharmaceuticals' bendamustine formulation filing activity
Eagle Pharmaceuticals has built a multi-patent position around bendamustine HCl injection formulations, as evidenced by at least two issued patents (US11844783B2, US11872214B2) arising from closely related application families. Tracking Eagle's prosecution activity for continuation or divisional filings in this family may reveal whether the company is extending its claim perimeter into new formulation parameters, dosing regimens, or excipient combinations relevant to BELRAPZO and its successors.
Eagle bendamustine portfolio watchBendamustine HCl injection patent filing trends across the industry
The bendamustine HCl injectable segment has attracted filings from multiple specialty pharma players seeking to differentiate on formulation stability, concentration, and excipient profiles. Mapping filing activity across this technology cluster — including IND-stage formulation patents and ANDA-linked IP — can reveal where the next wave of infringement risk or white-space opportunity lies, particularly as BELRAPZO-adjacent formulations enter development pipelines.
Bendamustine HCl filing trendsBaxter's patent position in injectable oncology drug delivery
Baxter International operates a significant injectable drug delivery and oncology portfolio. Assessing Baxter's own patent filings in the bendamustine and broader injectable cytotoxic drug space can reveal whether it is pursuing formulation innovation, alternative delivery systems, or compounding-adjacent technologies that may intersect with — or diverge from — Eagle's IP perimeter going forward. Baxter's post-settlement R&D trajectory in this segment is a relevant competitive signal.
Baxter injectable oncology IPAdjacent formulation innovation space near BELRAPZO claim scope
With Eagle's two patents intact and no public claim-scope narrowing from this litigation, the boundaries of protected formulation space around BELRAPZO remain as filed. Innovators and generic developers can use claim mapping tools to identify adjacent formulation parameters — alternative excipients, concentrations, or delivery formats — that may fall outside the asserted claim scope and represent viable white-space opportunities in the bendamustine HCl injection market.
Bendamustine formulation white spaceSimilar bendamustine and specialty pharma patent cases in Delaware
Browse patent infringement cases involving injectable oncology drug formulations litigated in the Delaware District Court, the primary venue for specialty pharma IP disputes.
What this case signals for the bendamustine and oncology pharma IP landscape
A 838-day Delaware patent dispute over a bendamustine injection carries forward-looking signals for specialty pharma IP strategy and competitor risk.
Eagle's BELRAPZO patents survive with no adverse validity ruling
Because Baxter's counterclaims were dismissed as moot — not adjudicated — US11844783B2 and US11872214B2 carry no court-imposed invalidity risk from this proceeding. Any competitor assessing freedom-to-operate in the bendamustine HCl injection space must treat these patents as fully enforceable. The absence of a merits ruling on validity may also deter future challengers from assuming a litigation shortcut.
Court-retained jurisdiction signals a structured, enforceable settlement
The Delaware District Court's retention of jurisdiction to enforce the settlement agreement is a structural signal that the resolution involves ongoing obligations between the parties — not simply a walk-away. IP professionals monitoring Eagle and Baxter's commercial relationship in the bendamustine segment should note this structural feature, even though the specific terms are not disclosed in the available record.
Eagle v Baxter — key questions answered
Eagle Pharmaceuticals asserted two patents: US11844783B2 (application no. US18/081238) and US11872214B2 (application no. US18/081251). Both patents relate to BELRAPZO, Eagle's bendamustine hydrochloride injection product. The action was filed in the U.S. District Court for the District of Delaware on January 17, 2024.
The recorded basis of termination is Dismissed with Prejudice. The docket order states the parties entered a settlement agreement and filed a stipulated dismissal under FRCP 41(a)(1)(A)(ii) and 41(c). Eagle's claims were dismissed with prejudice; Baxter's counterclaims were dismissed as moot. All parties bear their own costs and fees. The specific terms of the settlement are not disclosed in the available record.
No. Baxter's counterclaims — which likely included invalidity challenges — were dismissed as moot without any merits adjudication. No court ruling was issued on the validity or enforceability of US11844783B2 or US11872214B2. Both patents remain in force and enforceable as of the case closing date.
The stipulated dismissal order states that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve any disputes arising under the settlement agreement. This means that if either party alleges the other has breached the settlement terms, they can return to Judge Jennifer L. Hall's court rather than filing a new action. The specific obligations governed by this retained jurisdiction are not disclosed in the available record.
The case ran for 838 days, from January 17, 2024 to May 4, 2026. Eagle Pharmaceuticals was represented by McCarter & English LLP, with attorneys including Kenneth G. Schuler and Daniel M. Silver among others. Baxter was represented by Potter Anderson & Corroon, LLP, with attorneys including Martin J. Black and Philip A. Rovner among others. The case was assigned to Judge Jennifer L. Hall.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.